SCHEMBL4848864

SCHEMBL4848864

O=C1CCCN1c1cccc(-c2ccc(CC34CCCN3C(=O)N(c3cc(Cl)cc(Cl)c3)C4=O)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
F10 P00742 1/20 0.38
BRD4 O60885 1/20 0.37
BRDT Q58F21 1/20 0.37
PARP1 P09874 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.35
FNTA P49354 2/20 0.35
PGGT1B P53609 2/20 0.35
MAPT P10636 1/20 0.35
HCRTR1 O43613 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14254759 0.86 ITGAL (0.36) CYP3A4ITGB2ICAM1ITGALMCHR1
SCHEMBL7185871 0.84 PARP1 (0.33) LMNAHPGDTSHRNPC1RAB9A
SCHEMBL6218812 0.83 ITGAL (0.36) CYP2C9ITGB2ICAM1ITGALMCHR1
SCHEMBL4847498 0.83 ITGAL (0.39) TSHRALDH1A1ITGB2ICAM1ITGAL
SCHEMBL6215949 0.80 ITGAL (0.36) ITGB2ICAM1ITGALMCHR1
SCHEMBL14254855 0.79 ITGAL (0.46) TSHRKMT2AITGB2ICAM1ITGAL
SCHEMBL4840751 0.78 CNR1 (0.47) LMNAHPGDTSHRMCHR1
SCHEMBL6219120 0.78 CNR1 (0.37) LMNAHPGDTSHRALDH1A1KMT2A
SCHEMBL4844859 0.78 ITGAL (0.41) LMNAALDH1A1KMT2AMAPTITGB2
SCHEMBL4841707 0.77 ITGAL (0.55) ITGB2ICAM1ITGAL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342012-B2 Inhibitors of αLβ2 mediated cell adhesion MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-11 US disclosed
US-7342012-B2 Inhibitors of αLβ2 mediated cell adhesion MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-11 US disclosed
US-7342012-B2 Inhibitors of αLβ2 mediated cell adhesion MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-11 US disclosed
US-20050148602-A1 Inhibitors of alphaLbeta2 mediated cell adhesion TANABE SEIYAKU CO., LTD. 2005-07-07 US disclosed
US-6897225-B1 Inhibitors of αLβ2 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2005-05-24 US disclosed
EP-1307455-B1 INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION TANABE SEIYAKU CO (JP) 2005-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148602-A1 Inhibitors of alphaLbeta2 mediated cell adhesion ITGB2, ITGA2B, ITGB1 LMNA 482/4885HPGD 2803/4885TSHR 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.